Quintiles, Prodia in Central Lab Partnership

Quintiles has expanded its partnership with Jakarta-based Prodia Clinical Laboratory, through its sister company, Prodia the CRO, to facilitate rapid testing of samples from patients in clinical trials in Indonesia. Under the agreement, Prodia will provide Quintiles with exclusive access to Prodia’s harmonized central laboratory for a two-year period.

The pact will enable Quintiles’ customers to conduct clinical research in Indonesia and help establish the potential benefits of new medicines in the Indonesian population while contributing to global programs, according to a Quintiles statement.

“This agreement demonstrates Quintiles’ commitment to improving human health by increasing participation in global clinical research,” said Kerry Strydom, general manager of Quintiles Australia, New Zealand, Indonesia and Philippines, who also noted that major health issues in Indonesia’s ethnically diverse population of 240 million include infectious and non-communicable diseases, as well as an increase in tobacco-related illnesses.

“As new and improved medicines are developed for these conditions, it’s important that they are studied in populations for whom they are intended, including Indonesian patients.”
said Gunawan Prawiro Suharto, president of Prodia the CRO. “As the local market leader in laboratory services, Prodia is delighted to partner with Quintiles to help establish Indonesia as a true center of excellence for delivery of clinical trials. We look forward to working with Quintiles and its global biopharma customers to develop novel therapies.”